---
title: "Ascendis Pharma targets €200M SKYTROFA revenue and expands YORVIPATH globally in 2025"
date: "2025-02-13 07:04:17"
summary: "Earnings Call Insights: Ascendis Pharma (ASND) Q4 2024 Management View CEO Jan Mikkelsen highlighted 2024 as a pivotal year, with SKYTROFA achieving €200 million in revenue and a 6.5% share of the U.S. growth hormone market. The product now holds 45% of the U.S. long-acting growth hormone market. Mikkelsen announced..."
categories:
  - "seekalpha"
lang:
  - "en"
translations:
  - "en"
tags:
  - "seekalpha"
menu: ""
thumbnail: ""
lead: ""
comments: false
authorbox: false
pager: true
toc: false
mathjax: false
sidebar: "right"
widgets:
  - "search"
  - "recent"
  - "taglist"
---

Earnings Call Insights: Ascendis Pharma ([ASND](https://seekingalpha.com/symbol/ASND "Ascendis Pharma A/S")) Q4 2024

### Management View

* CEO Jan Mikkelsen highlighted 2024 as a pivotal year, with SKYTROFA achieving €200 million in revenue and a 6.5% share of the U.S. growth hormone market. The product now holds 45% of the U.S. long-acting growth hormone market.
* Mikkelsen announced the commercial launch of YORVIPATH in the U.S., with 908 unique patient prescriptions as of February 7, 2025. The product targets the treatment of hypoparathyroidism and is positioned as a potential multi-billion-dollar product.
* TransCon CNP data demonstrated superior linear growth benefits for achondroplasia, with plans to submit an NDA to the FDA in Q1 2025 and an MAA to the EU in Q3 2025.
* CFO Scott Smith confirmed a strong financial position with €665 million in cash, supported by a $100 million upfront payment from Novo Nordisk. He noted, "Total revenue for the fourth quarter was €173.9 million, including revenue recognition of the Novo Nordisk collaboration."

### Outlook

* Management expects continued growth for SKYTROFA through label expansions, including adult growth hormone deficiency, with a PDUFA date set for July 27, 2025.
* The company anticipates commercial launches for YORVIPATH in additional European countries and international markets in 2025. Mikkelsen stated, "We expect to add five or more countries this year."
* For TransCon CNP, topline results from the Phase 2 COACH Trial combining TransCon CNP with TransCon Growth Hormone are expected in Q2 2025.
* Plans are in place to initiate a basket trial for SKYTROFA, targeting indications such as idiopathic short stature and Turner syndrome.

### Financial Results

* SKYTROFA generated €58.5 million in Q4 2024 revenue, benefiting from a favorable sales adjustment of €4.6 million. Sequential volume growth for Q4 was 16%.
* YORVIPATH reported €13.6 million in Q4 revenue, contributing to a full-year total of €28.7 million. Initial U.S. demand has been strong, with 80% of enrolled patients being new to the product and payer discussions progressing positively.
* Total operating expenses for Q4 were €159.5 million, a slight increase from €154.9 million in Q4 2023, driven by investments in commercial expansion.

### Q&A

* Jessica Fye, JPMorgan: Asked about the 908 YORVIPATH prescriptions and patient breakdown. Jay Wu clarified, "20% of these are existing patients from clinical trials or expanded access programs, while 80% are new to YORVIPATH."
* Tazeen Ahmad, Bank of America: Inquired about YORVIPATH patient conversion rates and previous experience with NATPARA. Jan Mikkelsen acknowledged challenges in obtaining precise data but emphasized positive reimbursement progress across 35 states.
* Gavin Clark-Gartner, Evercore ISI: Questioned payer discussions for YORVIPATH. Jay Wu confirmed productive conversations and alignment with the product label, stating, "We are seeing approvals across commercial and government payers."
* Yaron Werber, TD Cowen: Asked about potential profitability. Scott Smith highlighted YORVIPATH's profitability as a key driver, supported by U.S. and European launches.

### Sentiment Analysis

* Analysts showed cautious optimism regarding YORVIPATH’s U.S. launch but sought clarity on reimbursement timelines and patient conversions. Their tone was neutral to slightly positive.
* Management maintained a confident tone in prepared remarks, emphasizing SKYTROFA’s growth and YORVIPATH’s market potential. During Q&A, responses were detailed but occasionally cautious, particularly on reimbursement and patient data.
* Compared to the previous quarter, management demonstrated increased confidence in YORVIPATH’s global rollout and SKYTROFA’s label expansion.

### Quarter-over-Quarter Comparison

* Guidance language shifted toward optimism, with clearer timelines for YORVIPATH’s global rollout and SKYTROFA’s adult label expansion.
* Strategic focus expanded to include basket trials and combination therapies for achondroplasia, highlighting innovation in growth disorder treatments.
* Analyst concerns remained focused on YORVIPATH’s reimbursement and patient adoption, consistent with the prior quarter.
* Management’s confidence in financial sustainability improved, supported by a robust cash position and Novo Nordisk collaboration.

### Risks and Concerns

* Management noted challenges in YORVIPATH’s reimbursement process, with timelines of four to eight weeks for insurance approvals.
* Analyst concerns centered on the competitive landscape for YORVIPATH and the potential impact of emerging therapies.
* Uncertainty remains regarding the pace of YORVIPATH’s international market penetration due to varying regulatory and reimbursement environments.

### Final Takeaway

Ascendis Pharma ended 2024 with strong momentum, driven by SKYTROFA’s revenue growth and YORVIPATH’s U.S. launch. With €665 million in cash and multiple product expansions planned for 2025, the company is well-positioned for sustained growth in rare endocrinology markets. Management’s focus on label expansions, innovative trials, and global market penetration underscores its ambition to achieve blockbuster status for its key products.

[Read the full Earnings Call Transcript](https://seekingalpha.com/symbol/ASND/earnings/transcripts)

[seekalpha](https://seekingalpha.com/news/4407414-ascendis-pharma-targets-200m-skytrofa-revenue-and-expands-yorvipath-globally-in-2025)
